GENOME ANNOUNCEMENT {#s1}
===================

Salmonella enterica remains one of the most common foodborne pathogens causing illnesses leading to numerous hospitalizations and causing millions of dollars in health care costs and productivity losses ([@B1], [@B2]). Within the food industry, Salmonella spp. have been shown to possess the ability to form biofilms on processing equipment ([@B3], [@B4]). This ability can confer resistance to disinfection and allow bacteria to persist over time and serve as a reservoir for future contamination ([@B5]). Salmonella enterica serovar Enteritidis is one of the primary serovars associated with human illnesses in the United States and is often associated with the consumption of contaminated poultry products ([@B6]). S. enterica serovar Kentucky has been identified as one of the more commonly isolated serovars from poultry production and often possesses a multidrug resistance phenotype ([@B6]). Although S. Kentucky has been affiliated with fewer hospitalizations than other Salmonella serovars, it has demonstrated the ability to obtain and spread plasmids that contribute to increased virulence and colonization in poultry ([@B7]). These abilities could become problematic if the strains are allowed to persist in processing and storage environments.

Four strains of S. enterica isolated from retail poultry carcasses from Arkansas were sequenced ([Table 1](#tab1){ref-type="table"}) ([@B8]). Of these, two (CFS84 and CFS85) belonged to serovar Kentucky and two to serovar Enteritidis (CFS86 and CFS87). Phenotypic testing of the S. Enteritidis strains showed wild-type morphologies and biofilm growth, while the S. Kentucky strains exhibited morphologies and growth associated with increased extracellular matrix component production (our unpublished data). All strains were previously found to exhibit resistance to multiple antimicrobial agents, with each strain showing resistance to sulfisoxazole and novobiocin. Strain CFS84 demonstrated additional resistance to neomycin, and CFS86 encoded resistance to ampicillin and nalidixic acid as well. Both S. Kentucky strains were detected to carry plasmids identified as incompatibility type I1 (IncI1), while both S. Enteritidis strains carried IncFIIA plasmids ([@B8]). Analysis of the genome sequences may be useful in identifying mitigation strategies to control Salmonella spp. found in retail environments.

###### 

Summary of the genome sequence analyses of Salmonella enterica strains from poultry in Arkansas

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Strain   Serovar       No. of\   Assembly\   G+C\          No. of\                                       No. of functional\   GenBank accession no.
                         contigs   size (bp)   content (%)   CDSs[^*a*^](#ngtab1.1){ref-type="table-fn"}   proteins             
  -------- ------------- --------- ----------- ------------- --------------------------------------------- -------------------- -------------------------------------------------------------------
  CFS84    Kentucky      232       4,935,761   51.99         5,081                                         4,293                [PHUN00000000](https://www.ncbi.nlm.nih.gov/nuccore/PHUN00000000)

  CFS85    Kentucky      151       4,908,583   51.98         4,987                                         4,230                [PHUO00000000](https://www.ncbi.nlm.nih.gov/nuccore/PHUO00000000)

  CFS86    Enteritidis   128       4,665,166   52.13         4,724                                         4,159                [PHUP00000000](https://www.ncbi.nlm.nih.gov/nuccore/PHUP00000000)

  CFS87    Enteritidis   95        4,656,278   52.14         4,705                                         4,136                [PIJU00000000](https://www.ncbi.nlm.nih.gov/nuccore/PIJU00000000)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CDSs, coding sequences.

To carry out whole-genome sequencing, total bacterial DNA was extracted using a DNeasy blood and tissue kit (Qiagen, Valencia, CA, USA). DNA libraries were constructed using the Nextera XT DNA sample kits (Illumina, San Diego, CA, USA). Sequencing reactions were carried out on an Illumina MiSeq instrument to generate 2 × 300 paired-end reads ([@B9]). Trimming and *de novo* assembly were performed using CLC Genomics Workbench version 9 (Qiagen, Germantown, MD, USA). Annotation of the draft genomes was done using Rapid Annotations using Subsystems Technology (RAST) ([@B10]), Pathosystems Resource Integration Center (PATRIC) ([@B11]), and the NCBI Prokaryotic Genome Automatic Annotation Pipeline (PGAAP) ([@B12]) ([Table 1](#tab1){ref-type="table"}). [Table 1](#tab1){ref-type="table"}lists the numbers of contigs, predicted coding sequences, and functional proteins, as well as the G+C content for each of the sequenced strains.

Accession number(s). {#s1.1}
--------------------

This whole-genome shotgun project has been deposited at DDBJ/ENA/GenBank under the accession numbers listed in [Table 1](#tab1){ref-type="table"}.
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